86 related articles for article (PubMed ID: 4518824)
1. Unusual cellular reaction to malignant melanoma in patients infused with cultured autochthonous lymphocytes.
Suk D; Pickren J; Moore GE
N Y State J Med; 1973 Oct; 73(20):2479-83. PubMed ID: 4518824
[No Abstract] [Full Text] [Related]
2. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
3. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
[No Abstract] [Full Text] [Related]
4. [Evidence for tumor immunity in human malignant melanoma].
Nagel GA
Schweiz Med Wochenschr; 1970 Jun; 100(23):995-1000. PubMed ID: 4947017
[No Abstract] [Full Text] [Related]
5. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
6. [Use of immunotherapy in the treatment of malignant melanoma of the skin].
Kristensen E
Ugeskr Laeger; 1976 Feb; 138(8):468-73. PubMed ID: 1258215
[No Abstract] [Full Text] [Related]
7. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
9. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
Adler A; Stein JA; Kedar E; Naor D; Weiss DW
J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
[TBL] [Abstract][Full Text] [Related]
10. Malignant melanoma.
Moore GE; Gerner RE
Surg Gynecol Obstet; 1971 Mar; 132(3):427-36. PubMed ID: 5546295
[No Abstract] [Full Text] [Related]
11. [Future of malignant stage I melanoma. Immunology and immunotherapy].
Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
[No Abstract] [Full Text] [Related]
12. [Immunology and melanoma. Theoretical-experimental observations].
Jurado A; Céspedes de Gómez M
Alergia; 1981 Oct; 28(4):145-72. PubMed ID: 7332071
[No Abstract] [Full Text] [Related]
13. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
15. Cutaneous malignant melanoma: a fresh outlook.
Kernohan NM
J Pathol; 1991 Apr; 163(4):283-5. PubMed ID: 2033487
[No Abstract] [Full Text] [Related]
16. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
17. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
18. [Active specific immunotherapy of malignant melanoma].
Lotem M; Shiloni E; Ingber A; Peretz T
Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
[No Abstract] [Full Text] [Related]
19. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
Enk AH; Becker JC; Schuler G
J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]